IDEA Collider | Carinne Brouillon, Edward Hæggström, Rob Scott | Pharma Innovation Summit

Carinne Brouillon is a Member of the Board of Managing Directors, with responsibility for the Human Pharma Business Unit

Professional milestones

• 2018 – 2019 Global Head of Therapeutic Areas, Boehringer Ingelheim
• 2014 – 2018 Head of Global Commercial Strategy Neuroscience at Janssen, Johnson & Johnson’s Pharmaceutical Company
• 2012 – 2018 President of Janssen Therapeutics and Member of the Janssen North America Leadership Team

Edward Hæggström Born 1969. Finnish citizen. Co-founder of Nanoform, CEO and a member of the Management Team since 2015.

Education: Ph.D. degree in applied physics from the University of Helsinki and a Master of Business Administration degree in innovation management from Helsinki University of Technology.

Experience: Dr. Hæggström has, among others, been a professor at the University of Helsinki and Head of the Electronics Research Laboratory within the Department of Physics. He has previously held the role of visiting professor of physics at Harvard Medical School, visiting scholar (assistant professor) of physics at Stanford University and project leader at the CERN.

Rob Scott, MD, a trained physician, has held leadership positions in global pharmaceutical companies for thirty years. During his career he has managed drug development teams responsible for highly successful pharmaceutical brands such as Norvasc, Lipitor, Repatha, Humira, Skyrizi and Rinvoq. Before retiring, his most recent position was Chief Medical Officer and Head of Development at AbbVie where he had oversight on all early and late-stage development programs. He was also responsible for a team of over 4,000 employees spanning 52 countries, a budget of close to $2 billion and programs involving approximately 40 new molecular entities. Before that, he was Vice President, Global Development TA Head and Head of Development Design Center at Amgen where he was responsible for the development of evolocumab (Repatha) the first approved PCSK9 inhibitor, ivabradine (Corlanor), to treat heart failure and omecamtiv mecarbil, a direct myosin activator for heart failure. From 2012 - 2016 he was a member of the US Food and Drug Administration’s Cardiovascular and Renal Drug Advisory Committee where he built strong relationships with senior FDA staff. Before Amgen, he held several leadership positions with emerging pharmaceutical and biotech companies. Dr. Scott is a graduate from the University of Cape Town, South Africa and started his career at Janssen as a Medical Advisor. He is a board member of Transclerate and a member of the PhRMA R&D Leadership Forum.